Loading
A phase 3 trial testing Oregovomab in ovarian cancer, active and no longer recruiting.
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is a phase 3 interventional study registered as NCT04498117, led by CanariaBio with Gynecologic Oncology and IQVIA Pty, and active but no longer recruiting on the registry. Official title: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. Planned enrolment is 615 participants (actual). The study started in 2020-08-25 and primary completion is expected in 2026-12-26. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/